Actinic Keratoses

Therapy Receives FDA Approval to Treat Common Skin Lesions

Published in Cancer Weekly, October 24th, 2000

Berlex Laboratories, Inc., Montville, New Jersey, and DUSA Pharmaceuticals, Inc., Wilmington, Massachusetts, announced that the U.S. Food and Drug Administration (FDA) has granted approval of the commercial BLU-U Blue Light Photodynamic Therapy Illuminator, used exclusively in the Levulan Photodynamic Therapy (PDT) System for treatment of non-hyperkeratotic actinic keratoses (AKs) of the face or scalp.

The Levulan PDT System is the first to use light-activated drugs to treat these common skin lesions. Distribution of the Levulan PDT System will begin immediately.

The active ingredient in the Levulan PDT System is aminolevulinic acid (ALA). This new...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-10-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry